|
Volumn 162, Issue 6, 2015, Pages 1186-1190
|
Releasing the Brakes on Cancer Immunotherapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;
IPILIMUMAB;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
ARTICLE;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CLINICAL RESEARCH;
DRUG TARGETING;
IMMUNE RESPONSE;
MALIGNANT NEOPLASTIC DISEASE;
PRIORITY JOURNAL;
T LYMPHOCYTE;
TARGET CELL;
ANIMAL;
AWARDS AND PRIZES;
HISTORY;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
MOLECULARLY TARGETED THERAPY;
NEOPLASMS;
UNITED STATES;
ANIMALS;
AWARDS AND PRIZES;
CTLA-4 ANTIGEN;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
IMMUNOTHERAPY;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
T-LYMPHOCYTES;
UNITED STATES;
|
EID: 84941343279
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2015.08.038 Document Type: Short Survey |
Times cited : (120)
|
References (15)
|